CD8A and hepatocellular carcinoma: Similar pro-inflammatory effects, leading to the increased infiltration of CD8+ cells and activation of the inflammasome, were also observed with another pan-DPP inhibitor, ARI-4175, in hepatocellular carcinoma models [69].